Company

BioMarin Pharmaceutical

BioMarin Pharmaceutical has 28 drugs tracked on RxWires: 4 post-market, 10 in Phase 3, 2 in Phase 2/3, 4 in Phase 2, 2 in Phase 1/2, 4 in Phase 1.

Pipeline

Drug	Phase	Indication
BH4	Post-Market	Pku Phenylketonuria
Pegvaliase	Post-Market	Phenylketonuria
saproterin dihydrochloride	Post-Market	Phenylketonuria
RDD to Palynziq	Post-Market	Phenylketonuria
BMN 111	Phase 3	Achondroplasia
Placebo	Phase 3	Mucopolysaccharidosis VI
Sapropterin Dihydrochloride	Phase 3	Phenylketonurias
BMN 110	Phase 3	Mucopolysaccharidosis IVA (Morquio A Syndrome)
INZ-701	Phase 3	Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency
Vosoritide	Phase 3	Hypochondroplasia
BMN 110 Weekly	Phase 3	MPS IV A
Kuvan®	Phase 3	Phenylketonuria
BMN 701	Phase 3	Late-onset Pompe Disease
Valoctocogene roxaparvovec	Phase 3	Hemophilia A
sapropterin	Phase 2/3	Behavioral Manifestations of Lesch-Nyhan Disease
BMN 333	Phase 2/3	Achondroplasia
BMN 165 (rAvPAL-PEG)	Phase 2	Phenylketonuria
BMN 351	Phase 2	Duchenne Muscular Dystrophy (DMD)
N-acetylgalactosamine 4-sulfatase	Phase 2	Mucopolysaccharidosis VI
Talazoparib Tosylate	Phase 2	Advanced Breast Cancer
Dose 1 of BMN 331	Phase 1/2	Hereditary Angioedema
PRO044 SC	Phase 1/2	Duchenne Muscular Dystrophy
rAvPAL-PEG	Phase 1	Phenylketonuria
BMN 349	Phase 1	Alpha 1-Antitrypsin Deficiency
Tetrahydrobiopterin 10 mg/kg	Phase 1	Claudication, Intermittent
Cisplatin	Phase 1	Solid Tumors
laronidase	Not Applicable	Cognitive Decline
Naglazyme®	Not Applicable	Maroteaux-Lamy Syndrome

Follow BioMarin Pharmaceutical on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.

Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.